Ipsen S.A.

Ipsen reported first-half 2026 total sales of EUR 2.2 billion, up 23.5% at constant exchange rates and 20.4% at current exchange rates. Core operating income rose 28.8% to EUR 845 million, gross margin was 85.1% of sales versus 86.1% last year, and the core operating margin improved 2.5 points to 38.6%. Free cash flow increased 34.9% to EUR 652 million, and net cash reached EUR 1 billion, up EUR 445 million versus December 2025. By segment, oncology sales grew 15.6% to EUR 1.45 billion, rare disease sales more than doubled to EUR 305 million, and neuroscience sales increased 16.6% to EUR 434 million. For 2026, Ipsen now expects sales growth of more than 20% at constant exchange rates and a core operating margin of more than 37% of sales. Management said the guidance assumes stronger Somatuline growth despite generic entry later in the second half, plus higher growth from Bylvay, IQIRVO, Dysport and new product contributions.

David Loew framed the first half as proof that Ipsen is executing on its strategy to accelerate growth in key medicines while expanding the pipeline. He repeatedly emphasized breadth of growth across the portfolio, calling out strong performances in rare disease and neuroscience alongside oncology, and he highlighted the company’s ability to combine near-term delivery with longer-term pipeline building. His tone was upbeat and confident, especially around the three positive Phase III readouts and the two new acquisitions, both of which he said fit Ipsen’s focus on sustainable growth beyond 2027.

Aymeric Le Chatelier stressed that the first half showed strength across sales, profitability and cash flow, with EUR 845 million of core operating income and EUR 652 million of free cash flow. He noted gross margin at 85.1%, SG&A at 27% of sales versus 30.8% last year, and R&D spending of over EUR 400 million, driven by pipeline investment, especially neuroscience and early oncology. He also highlighted net cash of EUR 1 billion and said Ipsen still has more than EUR 2 billion of pro forma firepower for external innovation after the Kartos and Memo transactions. On guidance, he said the upgrade reflects both Somatuline timing/pricing and strong momentum in the rest of the portfolio, while 2027 margin will be pressured by acquisition-related spending and migraine launch preparations.

Analysts pressed on Somatuline, asking why Ipsen expects stronger second-half performance despite generic launch timing concerns. Management said the forecast includes Amneal’s launch and that higher U.S. net pricing/gross-to-net dynamics should support sales even if volume eases. Questions on Bylvay focused on the softer quarter and the biliary atresia setback; management said underlying demand remains strong in PFIC and Alagille and that the BA data are still being analyzed. The call also covered Dysport migraine, where management said it wants to penetrate both chronic and episodic segments, expects higher commercial investment including DTC and field force expansion, and sees potential launch in the second half of 2027, subject to approvals.